Participated · Series A · Mar 2026

Kupando develops therapies addressing unmet needs in cancer and infectious diseases by harnessing innate immune stimulation and induction of trained innate immunity via dual Toll‑Like Receptor (TLR) agonists. Its lead candidate, KUP101, is a differentiated dual TLR4 and TLR7 agonist with a preclinical profile and a stated clear path to the clinic. The company plans to use the newly raised Series A funds to advance KUP101’s Phase 1b clinical study in advanced solid tumors and to accelerate its infectious‑disease preclinical programs. Kupando is led by CEO and Founder Johanna Holldack and is based in Schönefeld, Germany. Financially, the latest €10M Series A tranche brought the total capital raised to $23M.

Participated · Seed · May 2023

Nia Health develops clinical diagnosis and therapy systems and digital medical apps (including Nia for atopic dermatitis and Sorea for psoriasis) that combine machine vision, natural language processing and teledermatology. The company is a Charité Universitätsmedizin Berlin spin-off and works closely with German patient associations and leading clinicians. Its machine-vision approach enables accurate documentation of disease and therapy progression and optimized treatment, and its digital products were the first of their kind to be approved worldwide. Nia Health already provides daily support for thousands of patients and has customers in the insurance and pharmaceutical industries. The company plans to use new funding to expand market share in German-speaking countries, launch in other EU countries within the next 24 months, prepare for U.S. market entry, and further develop its AI-based technology.

Participated · Seed · Nov 2022

Navignostics combines AI-driven software with single-cell resolved spatial proteomic tumor data to guide targeted and immuno-oncology therapy selection tailored to each patient’s tumor phenotype. The company also offers advanced services to pharmaceutical companies to accelerate oncology drug development and enable discovery of companion diagnostic biomarkers. Navignostics is a spin-off from the University of Zurich and was founded in April 2022 by Jana Fischer, Stephane Chevrier, Andrea Jacobs and Bernd Bodenmiller. The team plans to use its recent financing to develop its first diagnostic product, establish certified processes, and move into dedicated laboratory and office premises. Management intends to expand engagement with clinical, biotech and pharma partners and grow its scientific and commercial team. No operating metrics (revenue/users) were disclosed in the article. Navignostics leverages spatial single-cell proteomics to perform advanced analyses of tumor samples aimed at identifying optimal treatments for individual cancer patients and accelerating cancer drug development. The company is developing the NX product to provide insights into drug mechanisms and tumor features for companion diagnostic development. Navignostics plans to use new funding to expand a world-leading team of scientists and business professionals and to boost NX product development. The company received an initial CHF1 million convertible loan from the UZH Life Sciences Fund to drive company and product development. Navignostics is a spin-off from Bernd Bodenmiller’s lab at the University of Zurich and was founded in April 2022 by Stephane Chevrier, Andrea Jacobs, Jana Fischer and Bernd Bodenmiller. The funding is described as an initial boost while the company is in the process of putting together a seed financing round.

Led · Seed · Oct 2022

IRUBIS develops Monipa, a spectroscopy-based process analytics (PAT) product for bioprocessing applications. The company positions Monipa to address monitoring challenges in both traditional antibody manufacturing and newer modalities. In August 2024 IRUBIS announced the close of a pre‑Series A funding round led by BioProcess360 Partners. Supporting investors named in the announcement include HTGF (High‑Tech Gründerfonds), Verve Ventures, Ventura BioMed Investors, RoBet KG and business angels Matthias Arnold and Dr. Christoph Bremus. Company leadership and investors framed the round as the start of a growth phase to further develop and commercialize their bioprocessing and spectroscopy capabilities. No financial amount or operating metrics were disclosed in the press release. IRUBIS is a Munich-based startup founded in September 2017 by Lorenz Sykora, Alexander Geißler and Anja Müller that develops process analytical technology for biopharmaceutical manufacturing. Its core product, Monipa, is a mid-infrared spectrometer system enabling real-time monitoring and prediction of metabolites, nutrients and protein quantity/quality during cell cultivation and purification. Monipa features a single-use interface and a simplifying calibration model and has been developed in close partnership with biopharma companies; it is already in use by key opinion leaders. The system is plug-and-play and designed to improve yield, product quality and shorten overall process development. IRUBIS raised EUR 2.8m in a seed financing round to scale operations, grow the team, increase sales and introduce the next Monipa version to market.

Participated · Series A · Oct 2021

Abalos Therapeutics is advancing a platform that harnesses the lymphocytic choriomeningitis virus (LCMV) to specifically target tumor cells. Using its proprietary Fast Evolution Platform the company generates viral variants with optimized anti‑tumoral properties to elicit a precise, directed immune response that can treat distant metastases and enable long‑term disease control. The lead program is being prepared for a Phase 1/2 trial in multiple solid tumors, including expansion cohorts to demonstrate early signs of clinical efficacy. The company intends to use the new funds to advance that first product candidate into clinical testing and to support further pipeline expansion. Abalos is led by CEO Dr. Marcus Kostka and is based in Dusseldorf. Financially, the company has raised a total of €43m (USD 50m) to date. Abalos Therapeutics is developing novel immuno-oncology therapeutics based on a specific arenavirus strain that preferentially infects and proliferates in cancer cells to generate strong anti-tumor immune responses. The company uses a proprietary Fast Evolution platform to generate virus strains with optimized anti-tumoral properties and will select candidates that re-program the immune system to eliminate malignant tissue. Proceeds from a €12 million Series A will be used to advance lead candidates toward clinical testing. Abalos builds on research from Prof. Dr. Karl Lang and Prof. Dr. Philipp Lang and maintains close collaborations with the Universities Duisburg‑Essen and Düsseldorf. The Series A established company operations and leadership in Essen, Germany, with Dr. Marcus Kostka named CEO and Dr. Jörg Vollmer named CSO. Investor representatives will join the company’s Supervisory Board as the team advances toward clinical evaluation.